The UK and US have announced a major bilateral deal that will guarantee zero duties on UK medicine shipments being sold in the US market.
Agreement Details of the Deal
Under the terms of the agreement, the UK has agreed to boost spending on drugs through the National Health Service (NHS). This move ensures that import taxes on these crucial products will stay at zero for a timeframe of three years.
This deal is in response to recent statements to dramatically increase tariffs on branded drug imports, with figures discussed as high as one hundred percent.
"This arrangement with the UK reinforces the international landscape for cutting-edge drugs and introduces long-overdue balance to transatlantic medicine commerce," a statement noted.
Trade Significance
Drugs are one of the Britain's largest export categories to the US, which is clearly the biggest destination for large UK drugmakers.
Export figures reveal that in the 12 months leading up to last September, the UK shipped pharmaceutical products valued at over eleven billion pounds to the US. This value represented 17.4% of total UK exports in that span.
"This deal secures work, increases capital expenditure and paves the way for the UK to become a international leader for life sciences," a minister remarked.
Key British Pledges
The pact entails several key changes from the UK:
- Revised Affordability Limit: The UK will increase the cost ceiling at which it considers new therapies to be unaffordable by twenty-five percent.
- Higher Drug Budget: There is a target to increase overall NHS spending on treatments from 0.3 percent of GDP to 0.6 percent over the next decade.
- Payback Limit: The percentage pharmaceutical firms must pay back to the NHS to control costs will be limited at fifteen percent. Previously, refunds were more than twenty percent.
Industry Background
This agreement takes place against a protracted row between the pharmaceutical industry and the ministers over spending levels and regulatory access.
These tensions were exacerbated by arguments that US patients were paying a premium for the identical medicines than patients in the Britain and the EU.
Over the last 18 months, several large pharmaceutical investments in the UK have been paused or abandoned, while multi-billion-dollar investments have been pledged toward US facilities.
A senior figure acknowledged that the NHS had to increase expenditure on medicines, noting that its expenditure on drugs had decreased as a share of its overall budget over the previous ten-year period.
